Nonsmall Cell Lung Cancer
Conditions
Brief summary
Cancer and its treatment can have profound effects on skeletal muscle, the most well-recognized being atrophy, weakness and diminished oxidative capacity. These adaptations negatively impact quality of life, treatment decisions and survival. Despite these consequences, the factors promoting these adaptations remain poorly defined and understudied in human patients. To address this gap in knowledge, our goal in this study is to examine the role of muscle disuse as a regulator of muscle size and function in human cancer patients
Interventions
BEHAVIORALExercise
Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
Sponsors
University of South Carolina
University of Vermont
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 50-75 yrs of age * histologically-documented, stage III or IV non-small cell lung carcinoma (NSCLC) * estimated life expectancy \>6 mos * Karnofsky's performance score of ≥70
Exclusion criteria
* history, signs or symptoms of inflammatory or autoimmune disease * uncontrolled hypertension * heart or renal failure * exercise limitations from peripheral vascular disease or stroke * neuromuscular disease * knee/hip replacement * additional, actively-treated malignancy or history of malignancy, except non-melanoma skin cancer * taking medication that can have anti-coagulant effects that cannot be stopped prior to the muscle biopsy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cross-sectional area of skeletal muscle fibers | Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks | Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types |
| Single muscle fiber contractile function | Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks | Segments of chemically-skinned single human muscle fibers will be assessed for cellular and molecular contractile parameters under maximal calcium-activated conditions, with muscle fiber type determined post-measurement by gel electrophoresis |
| Mitochondrial content | Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks | Mitochondrial content will be assessed by electron microscopy. |
| Mitochondrial function | Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks | Mitochondrial function will be assessed on isolated mitochondria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Whole muscle isometric function | Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks | Whole muscle volitional contractile function will be measured by isometric Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks by isometric dynamometry. |
| Whole muscle isokinetic function | Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks | Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks by isokinetic dynamometry |
| Whole muscle size | Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks | Whole muscle size will be measured by computed tomography at the mid-thigh level. |
Countries
United States
Outcome results
None listed